In CD4+ T cells isolated from multiple sclerosis patients, simvastatin augmented the production of the suppressor of cytokine secretion (SOCS) 3 and 7, negative regulators of STAT/JAK signaling, together with the induction of IFN-γ, IL-4, and IL-27, whereas they inhibited STAT1 and STAT3 activation and decreased RORγt and IL-17A mRNA levels [244,245]. Here, STAT3 is linked to multiple sclerosis.